slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 82,411-82,440
Pages 3,950
Rows per page 30
Component
82,411-82,440 of 118,471
328
The slide uses a Q&A transcript format to support the thesis that the competitor product is unnecessary or inferior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
332
The slide uses a direct quote from an endocrinologist to undermine the primary endpoint of a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
337
Uses direct quotes from an investigator to undermine the credibility of clinical trial data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
338
The slide uses a Q&A transcript format to highlight potential misclassification of adverse events in a clinical trial.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
339
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
342
The slide uses a Q&A format to highlight the expert's negative sentiment toward the drug's efficacy and the company's investor materials.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
343
The slide presents a direct challenge to the commercial viability of 'Vykat' by highlighting a physician's preference for a cheaper, off-label alternative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
344
The slide uses a Q&A format to validate the expert's critique of the product's form factor.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
346
The slide uses highlighted text to emphasize critical quotes from medical experts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
348
The slide presents interview transcripts highlighting a lack of buzz at a major industry conference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
350
The slide presents a Q&A format highlighting expert skepticism regarding the drug's safety profile and market relevance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
354
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
358
The slide uses a Q&A format to highlight skepticism among medical professionals regarding a drug's marketing presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
362
The slide uses direct quotes from a pediatric endocrinologist to highlight concerns about the clinical management of diabetes risk associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
363
The slide highlights a discrepancy between the company's sales pitch and clinical best practices as perceived by an expert.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
364
The slide uses verbatim quotes from a consultation call to highlight a discrepancy between the company's risk management (handouts) and the physician's expectations of transient vs. permanent side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
367
The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
369
The slide highlights the endocrinologist's reluctance to prescribe the drug, noting that patient pressure was a primary driver for his involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
370
The slide uses a Q&A format to expose that the drug's popularity is manufactured by advocacy groups rather than medical demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
373
The slide uses direct quotes to frame the expert's skepticism and clinical concerns about the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
374
The slide uses a Q&A transcript format to expose potential flaws in clinical trial methodology and physician sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
375
The slide uses highlighted text to emphasize key phrases from the expert's transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
377
The slide uses a Q&A format to expose a gap in the company's support infrastructure.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
378
The slide uses a 'before-after' narrative structure to expose the contradiction between the physician's initial interest and his clinical assessment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
379
The slide uses a direct quote from a pediatric endocrinologist to undermine the drug's clinical value.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
383
The slide presents a quote from an anonymous pediatric endocrinologist criticizing Dr. Miller's influence and medical recommendations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
384
The slide uses a pull-quote style to highlight the expert's hesitation and lack of full support.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
385
The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
386
The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
391
The slide uses a 'quote-sandwich' technique: a summary paragraph followed by verbatim Q&A transcripts with highlighted key phrases.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit